Diagnosis, Monitoring, Prognostication and Treatment in Hepatocellular Carcinoma
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (29 March 2024) | Viewed by 2235
Special Issue Editor
Special Issue Information
Dear Colleagues,
Since the first tyrosine kinase inhibitor was approved for systemic treatment of advanced hepatocellular carcinoma (HCC) over a decade ago, there has been unprecedented progress in the management and understanding of HCC. Treatment options have been expanded to include immune checkpoint inhibitors, which have now become part of standard of care, and molecular profiling of HCC has identified important drivers that are leading to potentially actionable targets. In addition, newer interventional approaches have been successfully implemented in those with localized disease. Progress is still needed in identifying predictors of treatment response and to determine the role of earlier systemic treatment as adjunct therapy of localized disease. We invite researchers to address one of these topics in the management of HCC from early to late stage disease.
I look forward to receiving your contributions.
Dr. Yoo-Joung KoGuest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
